Association between Methylenetetrahydrofolate Reductase C677T Polymorphism and Susceptibility to Cervical Cancer: A Meta-Analysis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Yu, Lili ^a   Chang, Kai ^a   Han, Jian ^a   Deng, Shaoli ^a   Chen, Ming ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ALLELE; ARTICLE; ASIAN; CANCER INVASION; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNIC DIFFERENCE; FEMALE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); NEOPLASM INVASIVENESS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; UTERINE CERVICAL NEOPLASMS;

EID: 84874219876     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055835     Document Type: Article

References (32)

1. Echelman D, Feldman S, (2012) Management of cervical precancers: a global perspective. Hematol Oncol Clin North Am 26: 31-44.
2. Ferlay J SH, Bray F (2011) GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide: IARC CancerBase No.10 [Internet]. Lyon (France): International Agency for Research on Cancer; 2010. Available at: http://globocan.iarc.fr. Accessed November 6, 2011.
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19.
4. Sankaranarayanan R, Thara S, Esmy PO, Basu P, (2008) Cervical cancer: screening and therapeutic perspectives. Med Princ Pract 17: 351-364.
5. Josefsson AM, Magnusson PK, Ylitalo N, Sorensen P, Qwarforth-Tubbin P, et al. (2000) Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 355: 2189-2193.
6. Stankova J, Lawrance AK, Rozen R, (2008) Methylenetetrahydrofolate reductase (MTHFR): a novel target for cancer therapy. Curr Pharm Des 14: 1143-1150.
7. Misra UK, Kalita J, Srivastava AK, Agarwal S, (2010) MTHFR gene polymorphism and its relationship with plasma homocysteine and folate in a North Indian population. Biochem Genet 48: 229-235.
8. Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, et al. (1994) Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet 7: 195-200.
9. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, et al. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111-113.
10. Kim YI, (2009) Role of the MTHFR polymorphisms in cancer risk modification and treatment. Future Oncol 5: 523-542.
11. Prasad VVTS, Wilkhoo H, (2011) Association of the functional polymorphism C677T in the methylenetetrahydrofolate reductase gene with colorectal, thyroid, breast, ovarian, and cervical cancers. Onkologie 34: 422-426.
12. Tong SY, Kim MK, Lee JK, Choi SW, Friso S, et al. (2011) Common polymorphisms in methylenetetrahydrofolate reductase gene are associated with risks of cervical intraepithelial neoplasia and cervical cancer in women with low serum folate and vitamin B12. Cancer Causes & Control 22: 63-72.
13. Mostowska A, Myka M, Lianeri M, Roszak A, Jagodzinski PP, et al. (2011) Folate and choline metabolism gene variants and development of uterine cervical carcinoma. Clinical Biochemistry 44: 596-600.
14. Kohaar I, Kumar J, Thakur N, Hussain S, Niyaz MK, et al. (2010) Homocysteine levels are associated with cervical cancer independent of methylene tetrahydrofolate reductase gene (MTHFR) polymorphisms in Indian population. Biomarkers 15: 61-68.
15. Shekari M, Sobti RC, Kordi Tamandani DM, Suri V, (2008) Impact of methylenetetrahydrofolate reductase (MTHFR) codon (677) and methionine synthase (MS) codon (2756) on risk of cervical carcinogenesis in North Indian population. Arch Gynecol Obstet 278: 517-524.
16. Nandan NK, Wajid S, Biswas S, Juneja SS, Rizvi M, et al. (2008) Allelic variations in 5, 10-methylenetetrahydrofolate reductase gene and susceptibility to cervical cancer in Indian women. Drug Metab Lett 2: 18-22.
17. Ma XC WJ, Zhou Q, (2006) Relationship between Methylenetetrahydrofolate reductase polymorphismand cervical cancer susceptibility. Chin J Public Health Dec 22: 1427-1428.
18. Zoodsma M, Nolte IM, Schipper M, Oosterom E, van der Steege G, et al. (2005) Methylenetetrahydrofolate reductase (MTHFR) and susceptibility for (pre)neoplastic cervical disease. Hum Genet 116: 247-254.
19. Kang S, Kim JW, Kang GH, Park NH, Song YS, et al. (2005) Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecologic Oncology 96: 173-180.
20. Sull JW, Jee SH, Yi S, Lee JE, Park JS, et al. (2004) The effect of methylenetetrahydrofolate reductase polymorphism C677T on cervical cancer in Korean women. Gynecologic Oncology 95: 557-563.
21. Lambropoulos AF, Agorastos T, Foka ZJ, Chrisafi S, Constantinidis TC, et al. (2003) Methylenetetrahydrofolate reductase polymorphism C677T is not associated to the risk of cervical dysplasia. Cancer Letters 191: 187-191.
22. Piyathilake CJ, Macaluso M, Johanning GL, Whiteside M, Heimburger DC, et al. (2000) Methylenetetrahydrofolate reductase (MTHFR) polymorphism increases the risk of cervical intraepithelial neoplasia. Anticancer Res 20: 1751-1757.
23. Galbraith RF, (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7: 889-894.
24. Prasad VV, Wilkhoo H, (2011) Association of the functional polymorphism C677T in the methylenetetrahydrofolate reductase gene with colorectal, thyroid, breast, ovarian, and cervical cancers. Onkologie 34: 422-426.
25. Ulvik A, Ueland PM, Fredriksen A, Meyer K, Vollset SE, et al. (2007) Functional inference of the methylenetetrahydrofolate reductase 677C>T and 1298A>C polymorphisms from a large-scale epidemiological study. Hum Genet 121: 57-64.
26. Goodman MT, McDuffie K, Hernandez B, Wilkens LR, Selhub J, (2000) Case-control study of plasma folate, homocysteine, vitamin B(12), and cysteine as markers of cervical dysplasia. Cancer 89: 376-382.
27. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62: 1006-1012.
28. Stang A, (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25: 603-605.
29. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
30. DerSimonian R, Kacker R, (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28: 105-114.
31. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
32. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.